Addition of PCSK9 Inhibitors and Ezetimibe to Statin Therapy for Cardiovascular Risk Reduction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BMJ: British Medical Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
BMJ 2022 May 04;377(xx)e069116, SU Khan, SH Yedlapati, AN Lone, Q Hao, G Guyatt, N Delvaux, GET Bekkering, PO Vandvik, IB Riaz, S Li, B Aertgeerts, N RodondiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.